You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Legend Biotech reported Carvicti net trade sales up approximately 36% year-over-year to $710 million and adjusted net income of $55.6 million. It expects full year 2026 company-wide profitability on an adjusted net income basis and double-digit Carvicti growth in 2027.
Legend Biotech reported $359.5 million revenue and $51.7 million net income for the three months ended September 30, 2026, versus a $39.6 million loss a year earlier. CARVYKTI net trade sales rose 36% to approximately $710 million.
Legend Biotech will present CARVYKTI analyses and LB2501 and LUCAR-G39D updates at the ASH Annual Meeting. CITADEL found a 1.6% IEC-parkinsonism rate versus 2.9% historically, while LB2501 achieved 100% response rates among eight patients.
Legend Biotech announced the U.S. Food and Drug Administration cleared LB2501’s IND application on October 15, 2026, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance and supporting a planned U.S. Phase 1/2 study.
Legend Biotech announced that CARVYKTI generated approximately $710 million in net trade sales during the quarter ended September 30, 2026; the figure was provided by Janssen and has not been independently verified.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LEGN
this stock
Legend Biotech Corp
|
$3.39B | -19.5% | — | — | 6.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Legend Biotech reported $359.5 million revenue and $51.7 million net income for the three months ended September 30, 2026, versus a $39.6 million loss a year earlier. CARVYKTI net trade sales rose 36% to approximately $710 million.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LEGN | -25.2% | -5.3% | -40.7% | -19.1% | -19.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -27.8% | -4.1% | -41.2% | -18.9% | -30.1% |
